Kidney cancer therapy: New perspectives and avenues

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 18, 2006, Pages 2481-2493

  Alexandrescu, Doru T ^a   Dasanu, Constantin A ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BAY 490006; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; EGF 2001; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IMATINIB; INTERFERON; INTERLEUKIN 2; LAPATINIB; MEGESTROL; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PEGINTERFERON ALPHA2B; PLACEBO; SORAFENIB; SU 11246; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB; VINBLASTINE; XL 880;

ACNE; ALOPECIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; LOW DRUG DOSE; LUNG METASTASIS; METABOLIC DISORDER; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; NEUTROPENIA; NONHUMAN; ORAL MUCOSAL DISEASE; PANCREATITIS; PROTEINURIA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISCOLORATION; SKIN TOXICITY; STOMATITIS; SYSTEMIC THERAPY; TASTE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; WOUND DEHISCENCE; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS;

EID: 33845578926     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.18.2481     Document Type: Review

References (86)

1. LINEHAN WM, ZBAR B, BATES SE et al.: Cancer of the kidney and ureter. In: Cancer. Principles and Practice of Oncology, 6th edn. DeVita VT Jr, Hellman S, Rosenberg SA (Eds), Lippincott, Williams & Wilkins, Philadelphia, PA (2001):1362-1396.
2. ARON M, GILL IS: Renal tumor ablation. Curr. Opin. Urol. (2005) 5:298-305.
3. BUKOWSKI RM, NOVICK AC: Clinical practice guidelines: renal cell carcinoma. Cleve. Clin. J. Med. (1997) 64(1):1-44.
4. KUEBLER JP, WHITEHEAD RP, WARD DL et al.: Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells. J. Urol. (1993) 150(3):814-820.
5. GEERTSEN PF, HERMANN GG, VON DER MAASE H et al.: Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center Phase II study. J. Clin. Oncol. (1992) 10(5):753-759.
6. COONEY MM, REMICK SC, VOGELZANG NJ: Promising systemic therapy for renal cell carcinoma. Curr. Treat. Options Oncol. (2005) 6(5):357-365.
7. COPPIN C, PORZSOLT F, AWA A et al.: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. (2005) 25(1):CD001425.
8. KONDAGUNTA GV, BACIK J, ISHILL N et al.: Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): results of a Phase II clinical trial and biologic correlates of response. J. Clin. Oncol. (2006) 24(18S):Abstr. 4528.
9. ILSON DH, MOTZER RJ, KRADIN RL et al.: A Phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J. Clin. Ontol. (1992) 10(7):1124-1130.
10. NEGRIER S, ESCUDIER B, LASSET C et al.: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. (1998) 338(18):1272-1278.
11. MOTZER RJ, BACIK J, SCHWARTZ LH et al.: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2004) 22(3):454-463.
12. UPTON MP, PARKER RA, YOUMANS A et al.: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J. Immunother. (2005) 28(5):488-495.
13. AMATO RJ: Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann. Oncol. (2005) 16(1):7-15.
14. PATEL PH, CHAGANTI RS, MOTZER RJ: Targeted therapy for metastatic renal cell carcinoma. Br. J. Cancer (2006) 94(5):614-619.
15. HAINSWORTH JD, SOSMAN JA, SPIGEL DR et al.: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. (2005) 23(31):7889-7896.
16. GNARRA JR, TORY K, WENG Y et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. (1994) 7(1):85-90.
17. LATIF F, TORY K, GNARRA J et al.: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 260:1317-1320.
18. ILIOPOULOS O, LEVY AP, JIANG C et al.: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA (1996) 93(20):10595-10599.
19. ANANTH S, KNEBELMANN B, GRUNING W et al.: Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res. (1999) 59(9):22l0-2216.
20. CULY C: Bevacizumab: antiangiogenic cancer therapy. Drugs Today (2005) 41(1):23-36.
21. DR GRAMONT A, VAN CUTSEM E: Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology (2005) 69(3):46-56.
22. YANG JC: Bevacizumab for patients with metastatic renal cancer: an update. Clin. Cancer Res. (2004) 10:6367-6370.
23. YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349(5):427-434.
24. RIEDEL F, GOTTE K, LI M et al.: EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int. J. Oncol. (2002) 21(1):11-16.
25. BOZEC A, FISCHEL JL, MILANO G: Epidermal growth factor receptor/ angiogenesis dual targeting: preclinical experience. Curr. Opin. Oncol. (2006) 18(4):330-334.
26. BUKOWSKI RM, KABBINAVAR F, FIGLIN RA et al.: Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J. Clin. Oncol. (2006) 24(18S):Abstr. 4523.
27. HAINSWORTH JD, SOSMAN JA, SPIGEL DR et al.: Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): a Minnie Pearl Cancer Research Network Phase I/II trial. J. Clin. Oncol. (2005) 23(16S):Abstr. 4542.
28. THOMPSON DS, GRECO FA, SPIGEL DR et al.: Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: update of a multicenter Phase II trial. J. Clin. Oncol. (2006) 24(18S):Abstr. 4594.
29. RINI BI, HALABI S, TAYLOR J et al.: Cancer and Leukemia Group B 90206: a randomized Phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res. (2004) 10(8):2584-2586.
30. GREEN D, MEZA-JUNCO J, ARCE C et al.: Phase-II trial of thalidomide for patients with metastatic renal cell carcinoma (RCC). J. Clin. Oncol. (2005) 23(16S):Abstr. 4761.
31. FARRAY D, CLARK JI, KUZEL T, DUTCHER JP: A multicenter Phase II study of thalidomide in combination with interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinonsa (MRCC). J. Clin. Oncol. (2006) 24(18S):Abstr. 14636.
32. SAWHNEY R, BRESCIA F, KEANE T, CLARKE H, CHAUDHARY UB: Phase II trial of pegylated Interferon alpha-2b, GM-CSF, and Thalidomide in metastatic progressive renal cell carcinoma. J. Clin. Oncol. (2005) 23(16S):Abstr. 4800.
33. MARSH L, KHAN M, NEEDLE M, AMATO R: Phase II study of lenalidomide in patients (pts) with metastatic renal cell cancer (MRCC). J. Clin. Oncol. (2006) 24(18S):Abstr. 4533.
34. CHOUEIRI TK, DREICER R, RINI BI et al.: Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC). J. Clin. Oncol. (2006) 24(18S):Abstr. 4539.
35. FIGLIN RA, KONDAGUNTA GV, YAZJI S, MOTZER RJ, BUKOWSKI RM: Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC). J. Clin. Oncol. (2006) 24(18S):Abstr. 4535.
36. LEPPERT JT, LAM JS, YU H et al.: Targeting the vascular endothelial growth factor pathway in renal cell carcinoma: a tissue array based analysis. J. Clin. Oncol. (2005) 23(16S):Abstr. 4536.
37. KIM W, KAELLN WG JR: The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. (2003) 13(1):55-60.
38. MOTZER RJ, BANDER NH, NANUS DM: Renal-cell carcinoma. N. Engl. J. Med. (1996) 335(12):865-875.
39. GOLLOB JA: Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin. Genitourin Cancer. (2005) 4(3):167-174.
40. SMITH K, GUNARATNAM L, MORLEY M et al.: Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/-renal cancer. Cancer Res. (2005) 65(12):5221-5230.
41. PREWETT M, ROTHMAN M, WAKSAL H et al.: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin. Cancer Res. (1998) 4(12):2957-2966.
42. DAWSON NA, GUO C, ZAK R et al.: A Phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin. Cancer Res. (2004) 10(23):7812-7819.
43. MOTZER RJ, AMATO R, TODD M et al.: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest. New Drugs (2003) 21(1):99-101.
44. SPIGEL DR, HAINSWORTH JD, SOSMAN JA et al.: Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): update of a Phase II multicenter trial. J. Clin. Oncol. (2005) 23(16S):Abstr. 4540.
45. BUKOWSKI RM, KABBINAVAR F, FIGLIN RA et al.: Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J. Clin. Oncol. (2006) 24(18S):Abstr. 4523.
46. GEMMILL RM, ZHOU M, COSTA L et al.: Synergistic growth inhibition by Iressa and rapamycin is modulated by vhl mutations in renal cell carcinoma. Br. J. Cancer. (2005) 92(12):2266-2277.
47. BEERAM M, PATNAIK A, ROWINSKY EK: Raf: a strategic target for therapeutic development against cancer. J. Clin. Oncol. (2005) 23(27):6771-6790.
48. MANNING G, WHYTE DB, MARTINEZ R et al.: The protein kinase complement of the human genome. Science (2002) 298:1912-1934.
49. CLARK JW, EDER JP, RYAN D et al.: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. (2005) 11(15):5472-5480.
50. AHMAD T, EISEN T: Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. (2004) 10:6388-6392.
51. WILHELM SM, CARTER C, TANG L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. (2004) 64(19):7099-7109.
52. STRUMBERG D, RICHLY H, HILGER RA et al.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. (2005) 23(5):965-972.
53. WILHELM S, CHIEN DS: BAY 43-9006: preclinical data. Curr. Pharm. Des. (2002) 8(25):2255-2257.
54. AL HAZZOURI A, VAZIRI SA, LYNCH M et al.: Anti-proliferative effects of sorafenib in clear cell renal cell carcinoma (CCRCC) cell lines: relationship to von Hippel Lindau protein (pVHL) expression and hypoxia. J. Clin. Oncol. (2006) 24(18S):Abstr. 4601.
55. SUN L, LIANG C, SHIRAZIAN S et al.: Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dim ethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. (2003) 46(7):1116-1119.
56. MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. (2003) 9(1):327-337.
57. FAIVRE S, DELBALDO C, VERA K et al.: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. (2006) 24(1):25-35.
58. ESCUDIER B, SZCZYLIK C, EISEN T et al.: Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY-9006) in patients with advanced renal cell carcinoma (RCC) Eur. J. Cancer Suppl. (2005) 3(2):226 Abstr. 794.
59. RATAIN MJ, EISEN T, STADLER WM et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(16):2505-2512.
60. EISEN T, BUKOWSKI RM, STAEHLER M et al.: For The Sorafenib TARGETs Clinical Trial Group. Randomized Phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. J. Clin. Oncol. (2006) 24(18S):Abstr. 4524.
61. DHANDA R, GONDEK K, SONG J, CELLA D, BUKOWSKI RM, ESCUDIER B: A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. J. Clin. Oncol. (2006) 24(18S):Abstr. 4534.
62. ESCUDIER B, SZCZYLIK C, DEMKOW T et al.: Randomized Phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. (2006) 24(185):Abstr. 4501.
63. MOTZER RJ, MICHAELSON MD, REDMAN BC et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(1):16-24.
64. MOTZER RJ, RINI B, MICHAELSON MD et al.: Sunitinib malate (SU11248) shows antitumour activity in patients with metastatic renal cell carcinoma: updated results from Phase II trials. Eur. J. Cancer Suppl. (2005) 3(2):227 Abstr. 797.
65. MOTZER RJ, RINI BI, BUKOWSKI RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 295(21):2516-2524.
66. MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. (2006) 24(18S):Abstr. LBA3.
67. TAMASKAR I, SHAHEEN P, WOOD L et al.: Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. J. Clin. Oncol. (2006) 24(18S):Abstr. 4597.
68. DE MULDER PH, ROIGAS J, GILLESSEN S et al.: A Phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. (2006) 24(18S):Abstr. 4529.
69. RONNEN EA, KONDAGUNTA GV, LAU C et al.: A Phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. (2006) 24(18S):Abstr. 4537.
70. SUPPIAH R, FINKE J, RINI BI et al.: T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: Correlations with clinical responses and T helper 1/ T helper 2(Th1/Th2) bias. J. Clin. Oncol. (2006) 24(18S):Abstr. 2526.
71. BUKOWSKI RM, FIGLIN RA: Multitargeted therapy in kidney cancer. In: Oncology Consultations. Physician's Education Resourse Publication. (2006) 3(4):1-10.
72. RINI B, RIXE O, BUKOWSKI R et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase II study of cytokine-refractory, metastatic renal-cell cancer (RCC). J. Clin. Oncol. (2005) 23(Suppl.):380s Abstr. 4509.
73. RINI BI: SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clin. Genitourin. Cancer (2005) 4(3):175-180.
74. WAKELEE HA, SCHILLER JH: Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clin. Lung Cancer (2005) 7(Suppl. 1):S31-S38.
75. HUTSON TE, BUKOWSKI RM: A Phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clin. Genitourin. Cancer (2006) 4(4):296-298.
76. MILLER KD, MILLER M, MEHROTRA S et al.: A physiologic imaging pilot study of breast cancer treated with AZD2171. Clin. Cancer Res. (2006) 12(1):281-288.
77. RAVAUD A, GARDNER J, HAWKINS R et al.: Tykerb. Renal Cell Cancer Study Group and GSK CoreT. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a Phase III trial in advanced renal cell carcinoma (RCC). J. Clin. Oncol. (2006) 24(18S):Abstr. 4502.
78. EDER JP, APPLEMAN L, HEATH E et al.: A Phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs). J. Clin. Oncol. (2006) 24(18S):Abstr. 3041.
79. RYAN CW, GOLDMAN BH, LARA PN et al.: Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. J. Clin. Oncol. (2006) 24(18S):Abstr. 4525.
80. GOLLOB J, RICHMOND T, JONES J et al.: Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). J. Clin. Oncol. (2006) 24(18S):Abstr. 4538.
81. POLITE BN, DESAI AA, PETERSON AC, MANCHEN B, STADLER WM: A Phase II study of imatinib mesylate (IM) and interferon-alpha (IFNA) in metastatic renal cell carcinoma (RCC). J. Clin. Oncol. (2005) 23:16S Abstr. 4689.
82. JAC J, ZHAI Q, KAREIDY M, HERNANDEZ J, MARSH L, AMATO R: Interferon-alpha (IFN) and gefitinib or imatinib in patients (pts) with metastatic renal cell carcinoma (RCC). J. Clin. Oncol. (2006) 24(18S):Abstr. 14616.
83. FIGLIN RA, SELIGSON D, WU H et al.: Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J. Clin. Oncol. (2005) 23(16S):Abstr. 4539.
84. DEL BUFALO D, CIUFFREDA L, TRISCIUOGLIO D et al.: Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. (2006) 66(11):5549-5554.
85. HUDES G, CARDUCCI M, TOMCZAK P et al.: A Phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J. Clin. Oncol. (2006) 24(18S):Abstr. LBA4.
86. PORTER LI., BURRIS HA, JONES SF et al.: Summary of results in patients with nsetastatic renal cell cancer (RCC) from Phase I studies of RAD001 (everolimus). J. Clin. Oncol. (2006) 24(18S):Abstr. 14599.